APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Factor VIII

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Factor VIII Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchRecombinant Factor VIII Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Factor VIII Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Recombinant Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Factor VIII Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Factor VIII Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Recombinant Factor VIII market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Factor VIII market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Factor VIII market include Takeda, NovoNordisk, Pfizer, Biogen, Bayer, Octapharma and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Factor VIII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Factor VIII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Factor VIII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Factor VIII market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Factor VIII Segment by Company

Takeda

NovoNordisk

Pfizer

Biogen

Bayer

Octapharma

CSL

Recombinant Factor VIII Segment by Type

200IU

250IU

Recombinant Factor VIII Segment by Application

Hospital

Pharmacy

Recombinant Factor VIII Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Factor VIII status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Factor VIII market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Factor VIII significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Factor VIII competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Factor VIII.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Factor VIII market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Factor VIII industry.

Chapter 3: Detailed analysis of Recombinant Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Factor VIII in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Factor VIII Industry Trends Table 2. Recombinant Factor VIII Industry Drivers Table 3. Recombinant Factor VIII Industry Opportunities and Challenges Table 4. Recombinant Factor VIII Industry Restraints Table 5. Global Recombinant Factor VIII Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Factor VIII Revenue Share by Company (2021-2026) Table 7. Global Recombinant Factor VIII Sales Volume by Company (units) & (2021-2026) Table 8. Global Recombinant Factor VIII Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Factor VIII Average Price (US$/unit) of Company (2021-2026) Table 10. Global Recombinant Factor VIII Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Factor VIII Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Factor VIII Company, Product Type & Application Table 13. Global Recombinant Factor VIII Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Factor VIII by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 200IU Table 18. Significant Companies of 250IU Table 19. Global Recombinant Factor VIII Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Recombinant Factor VIII Sales Volume by Type (2021-2026) & (units) Table 21. Global Recombinant Factor VIII Sales Volume by Type (2027-2032) & (units) Table 22. Global Recombinant Factor VIII Sales Volume Share by Type (2021-2026) Table 23. Global Recombinant Factor VIII Sales Volume Share by Type (2027-2032) Table 24. Global Recombinant Factor VIII Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Recombinant Factor VIII Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Recombinant Factor VIII Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Recombinant Factor VIII Sales Value Share by Type (2021-2026) Table 28. Global Recombinant Factor VIII Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Recombinant Factor VIII Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 32. Global Recombinant Factor VIII Sales Volume by Application (2021-2026) & (units) Table 33. Global Recombinant Factor VIII Sales Volume by Application (2027-2032) & (units) Table 34. Global Recombinant Factor VIII Sales Volume Share by Application (2021-2026) Table 35. Global Recombinant Factor VIII Sales Volume Share by Application (2027-2032) Table 36. Global Recombinant Factor VIII Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Recombinant Factor VIII Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Recombinant Factor VIII Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Recombinant Factor VIII Sales Value Share by Application (2021-2026) Table 40. Global Recombinant Factor VIII Sales Value Share by Application (2027-2032) Table 41. Global Recombinant Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (units) Table 42. Global Recombinant Factor VIII Sales by Region (2021-2026) & (units) Table 43. Global Recombinant Factor VIII Sales Market Share by Region (2021-2026) Table 44. Global Recombinant Factor VIII Sales by Region (2027-2032) & (units) Table 45. Global Recombinant Factor VIII Sales Market Share by Region (2027-2032) Table 46. Global Recombinant Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Recombinant Factor VIII Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Recombinant Factor VIII Sales Value Share by Region (2021-2026) Table 49. Global Recombinant Factor VIII Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Recombinant Factor VIII Sales Value Share by Region (2027-2032) Table 51. Global Recombinant Factor VIII Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Recombinant Factor VIII Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Recombinant Factor VIII Sales by Country: 2021 VS 2025 VS 2032 (units) Table 54. Global Recombinant Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Recombinant Factor VIII Sales by Country (2021-2026) & (units) Table 56. Global Recombinant Factor VIII Sales Market Share by Country (2021-2026) Table 57. Global Recombinant Factor VIII Sales by Country (2027-2032) & (units) Table 58. Global Recombinant Factor VIII Sales Market Share by Country (2027-2032) Table 59. Global Recombinant Factor VIII Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Recombinant Factor VIII Sales Value Market Share by Country (2021-2026) Table 61. Global Recombinant Factor VIII Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Recombinant Factor VIII Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Takeda Recombinant Factor VIII Product Portfolio Table 67. Takeda Recent Development Table 68. NovoNordisk Company Information Table 69. NovoNordisk Business Overview Table 70. NovoNordisk Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. NovoNordisk Recombinant Factor VIII Product Portfolio Table 72. NovoNordisk Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Pfizer Recombinant Factor VIII Product Portfolio Table 77. Pfizer Recent Development Table 78. Biogen Company Information Table 79. Biogen Business Overview Table 80. Biogen Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Biogen Recombinant Factor VIII Product Portfolio Table 82. Biogen Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Bayer Recombinant Factor VIII Product Portfolio Table 87. Bayer Recent Development Table 88. Octapharma Company Information Table 89. Octapharma Business Overview Table 90. Octapharma Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Octapharma Recombinant Factor VIII Product Portfolio Table 92. Octapharma Recent Development Table 93. CSL Company Information Table 94. CSL Business Overview Table 95. CSL Recombinant Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. CSL Recombinant Factor VIII Product Portfolio Table 97. CSL Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Recombinant Factor VIII Distributors List Table 101. Recombinant Factor VIII Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Recombinant Factor VIII Product Image Figure 2. Global Recombinant Factor VIII Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Factor VIII Sales (2021-2032) & (units) Figure 5. Global Recombinant Factor VIII Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Recombinant Factor VIII Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 200IU Image Figure 10. 250IU Image Figure 11. Global Recombinant Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Recombinant Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Recombinant Factor VIII Sales Volume Share by Type (2021-2032) Figure 14. Global Recombinant Factor VIII Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Factor VIII Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Recombinant Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 20. Global Recombinant Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Recombinant Factor VIII Sales Volume Share by Application (2021-2032) Figure 22. Global Recombinant Factor VIII Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Recombinant Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Factor VIII Sales Value Share by Application (2021-2032) Figure 25. Global Recombinant Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 26. Global Recombinant Factor VIII Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Recombinant Factor VIII Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 30. North America Recombinant Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Recombinant Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Recombinant Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 36. South America Recombinant Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Recombinant Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Recombinant Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Recombinant Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Recombinant Factor VIII Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Recombinant Factor VIII Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 200IU
  • 250IU
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Takeda
  • NovoNordisk
  • Pfizer
  • Biogen
  • Bayer
  • Octapharma
  • CSL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Factor VIII Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Factor VIII Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Factor VIII Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Factor VIII Market Dynamics
  1. 2.1 Recombinant Factor VIII Industry Trends
  2. 2.2 Recombinant Factor VIII Industry Drivers
  3. 2.3 Recombinant Factor VIII Industry Opportunities and Challenges
  4. 2.4 Recombinant Factor VIII Industry Restraints
3 Recombinant Factor VIII Market by Company
  1. 3.1 Global Recombinant Factor VIII Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Factor VIII Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Factor VIII Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Factor VIII Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Factor VIII Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Factor VIII Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Factor VIII Company Product Type and Application
  8. 3.8 Global Recombinant Factor VIII Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Factor VIII Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Factor VIII Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Factor VIII Market by Type
  1. 4.1 Recombinant Factor VIII Type Introduction
  2. 4.1.1 200IU
  3. 4.1.2 250IU
  4. 4.2 Global Recombinant Factor VIII Sales Volume by Type
  5. 4.2.1 Global Recombinant Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Factor VIII Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Recombinant Factor VIII Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Recombinant Factor VIII Sales Value by Type
  9. 4.3.1 Global Recombinant Factor VIII Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Factor VIII Sales Value by Type (2021-2032)
  11. 4.3.3 Global Recombinant Factor VIII Sales Value Share by Type (2021-2032)
5 Recombinant Factor VIII Market by Application
  1. 5.1 Recombinant Factor VIII Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Recombinant Factor VIII Sales Volume by Application
  5. 5.2.1 Global Recombinant Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Factor VIII Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Recombinant Factor VIII Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Recombinant Factor VIII Sales Value by Application
  9. 5.3.1 Global Recombinant Factor VIII Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Factor VIII Sales Value by Application (2021-2032)
  11. 5.3.3 Global Recombinant Factor VIII Sales Value Share by Application (2021-2032)
6 Recombinant Factor VIII Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Factor VIII Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Factor VIII Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Factor VIII Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Factor VIII Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Factor VIII Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Factor VIII Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Factor VIII Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Factor VIII Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Factor VIII Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Factor VIII Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Factor VIII Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Factor VIII Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Factor VIII Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Factor VIII Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Factor VIII Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Factor VIII Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Factor VIII Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Factor VIII Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Factor VIII Sales Value Share by Country, 2025 VS 2032
7 Recombinant Factor VIII Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Factor VIII Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Factor VIII Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Factor VIII Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Factor VIII Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Factor VIII Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Factor VIII Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Factor VIII Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Factor VIII Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Factor VIII Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Factor VIII Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Recombinant Factor VIII Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 NovoNordisk
  8. 8.2.1 NovoNordisk Company Information
  9. 8.2.2 NovoNordisk Business Overview
  10. 8.2.3 NovoNordisk Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 NovoNordisk Recombinant Factor VIII Product Portfolio
  12. 8.2.5 NovoNordisk Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Recombinant Factor VIII Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Biogen
  20. 8.4.1 Biogen Company Information
  21. 8.4.2 Biogen Business Overview
  22. 8.4.3 Biogen Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biogen Recombinant Factor VIII Product Portfolio
  24. 8.4.5 Biogen Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Recombinant Factor VIII Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Octapharma
  32. 8.6.1 Octapharma Company Information
  33. 8.6.2 Octapharma Business Overview
  34. 8.6.3 Octapharma Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Octapharma Recombinant Factor VIII Product Portfolio
  36. 8.6.5 Octapharma Recent Developments
  37. 8.7 CSL
  38. 8.7.1 CSL Company Information
  39. 8.7.2 CSL Business Overview
  40. 8.7.3 CSL Recombinant Factor VIII Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Recombinant Factor VIII Product Portfolio
  42. 8.7.5 CSL Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Factor VIII Value Chain Analysis
  2. 9.1.1 Recombinant Factor VIII Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Factor VIII Sales Mode & Process
  6. 9.2 Recombinant Factor VIII Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Factor VIII Distributors
  9. 9.2.3 Recombinant Factor VIII Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst